Pharvaris N.V. (NASDAQ:PHVS) Sees Large Increase in Short Interest

Pharvaris N.V. (NASDAQ:PHVS) was the recipient of a significant increase in short interest in the month of January. As of January 15th, there was short interest totaling 904,318 shares, an increase of 22.2% from the December 31st total of 739,825 shares. Based on an average trading volume of 240,394 shares, the short-interest ratio is presently 3.8 days. Based on an average trading volume of 240,394 shares, the short-interest ratio is presently 3.8 days.

Institutional Investors Weigh In On Pharvaris

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. GF Fund Management CO. LTD. bought a new stake in shares of Pharvaris in the 4th quarter valued at approximately $35,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new stake in Pharvaris in the second quarter valued at approximately $57,000. JPMorgan Chase & Co. grew its position in Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after acquiring an additional 783 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Pharvaris during the 3rd quarter worth $75,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Pharvaris during the 4th quarter valued at $86,000.

Pharvaris Trading Down 4.6%

Pharvaris stock opened at $26.54 on Thursday. Pharvaris has a twelve month low of $11.51 and a twelve month high of $29.80. The firm’s 50 day moving average price is $26.10 and its two-hundred day moving average price is $23.97.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.08. As a group, sell-side analysts expect that Pharvaris will post -2.71 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

PHVS has been the subject of several research reports. Leerink Partners set a $38.00 price objective on shares of Pharvaris in a research report on Wednesday, December 3rd. HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of Pharvaris in a report on Wednesday, December 3rd. Oppenheimer upped their price target on Pharvaris from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Thursday, December 4th. Bank of America raised their price objective on Pharvaris from $27.00 to $30.00 and gave the stock a “neutral” rating in a research note on Thursday, December 4th. Finally, Guggenheim boosted their target price on Pharvaris from $32.00 to $39.00 and gave the stock a “buy” rating in a research report on Thursday, December 4th. Nine equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Pharvaris presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.56.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.